Exchange: NASDAQ·Updated 04:16 PM EST

ZVRA News

News
all
press releases
Zevra Therapeutics (NASDAQ:ZVRA) Shares Climb 6.3% - What's Next?
Zevra Therapeutics (NASDAQ:ZVRA) Stock Price Up 6.3% - Still a Buy...
MarketBeat
Zevra Therapeutics (NASDAQ:ZVRA) Shares Climb 6.3% - What's Next?
Zevra Therapeutics (NASDAQ:ZVRA) Stock Price Up 6.3% - Still a Buy...
MarketBeat
More News
Guggenheim decreased their target price on shares of Zevra Therapeutics from $23.00 to $18.00 and set a "buy" rating on the stock in a research note on Monday...
MarketBeat
Zevra Therapeutics (NASDAQ:ZVRA) Share Price Crosses Below 200 Day Moving Average Following Analyst Downgrade...
MarketBeat
The Committee for Medicinal Products for Human Use confirmed its recommendation to refuse marketing authorisation for the medicine following a re-examination.
Stocktwits
The mean of analysts' price targets for Zevra Therapeutics (ZVRA) points to an 117.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of +28.57% and +2.77%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Zevra Therapeutics, Inc (Symbol: ZVRA), where a total volume of 8,827 contracts has been traded thus far today, a contract volume which is representative of appr...
Nasdaq News: Markets
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA PR Newswire NEW YORK, Aug. 6, 2026 NEW YORK, Aug. 6, 2026 /PRNewswire...
PR Newswire
Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of +212.50% and +22.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Zevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & Korsinsky Zevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & Korsinsky PR Newswire NEW YORK, Aug. 3, 2026 Zevra investors who relied on public statements about arimoclomol's approval status faced losses after the...
PR Newswire

Advertisement|Remove ads.